MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 10, Pages 4508-4517
Publisher
Proceedings of the National Academy of Sciences
Online
2019-02-02
DOI
10.1073/pnas.1817494116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
- (2018) Manuel Sanclemente et al. CANCER CELL
- Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
- (2018) Wenlin Shao et al. CANCER RESEARCH
- Differential Effector Engagement by Oncogenic KRAS
- (2018) Tina L. Yuan et al. Cell Reports
- Rationale for RAS mutation-tailored therapies
- (2017) Steven K Montalvo et al. Future Oncology
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
- (2017) Gisele A. Nishiguchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
- (2017) Xingyue He et al. Nature Chemical Biology
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
- (2017) Coralie Dorard et al. Nature Communications
- A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
- (2017) Timothy D. Martin et al. Cell Reports
- Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells
- (2016) Jessie Yanxiang Guo et al. GENES & DEVELOPMENT
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- (2016) J. E. Grilley-Olson et al. INVESTIGATIONAL NEW DRUGS
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Covalent Guanosine Mimetic Inhibitors of G12C KRAS
- (2016) Yuan Xiong et al. ACS Medicinal Chemistry Letters
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation
- (2016) Jordan L. Smith et al. Cell and Bioscience
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
- (2015) Christina H. Eng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma
- (2015) X. Xie et al. Cancer Discovery
- Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
- (2014) Sireesha V Garimella et al. BREAST CANCER RESEARCH
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
- (2014) B. Alagesan et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers
- (2014) C. F. Malone et al. Cancer Discovery
- Development of siRNA Payloads to Target KRAS-Mutant Cancer
- (2014) T. L. Yuan et al. Cancer Discovery
- Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
- (2014) A. Yang et al. Cancer Discovery
- Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance
- (2014) G. Karsli-Uzunbas et al. Cancer Discovery
- Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRASG12D-driven lung tumors
- (2013) Jessie Yanxiang Guo et al. Autophagy
- Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer
- (2013) Hyun Seok Kim et al. CELL
- Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
- (2013) Alyson K. Freeman et al. MOLECULAR CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Genetic Deletion of RALA and RALB Small GTPases Reveals Redundant Functions in Development and Tumorigenesis
- (2012) Pascal Peschard et al. CURRENT BIOLOGY
- C911: A Bench-Level Control for Sequence Specific siRNA Off-Target Effects
- (2012) Eugen Buehler et al. PLoS One
- Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells
- (2012) M.-T. Weng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- Early Requirement of Rac1 in a Mouse Model of Pancreatic Cancer
- (2011) Irina Heid et al. GASTROENTEROLOGY
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay
- (2011) Christof Fellmann et al. MOLECULAR CELL
- C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D
- (2011) Florian A. Karreth et al. Cancer Discovery
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
- (2010) Matthias Drosten et al. EMBO JOURNAL
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
- (2009) J. Yun et al. SCIENCE
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started